IP Library Granted Patent US 9,522,155
Granted Patent B2
US 9,522,155 · App. 14/503,273 · Granted Dec 20, 2016

Synthetic bile acid compositions and methods

Inventors: Robert M. Moriarty (Michiana Shores, IN); Nathaniel E. David (Los Angeles, CA); Nadir Ahmeduddin Mahmood (Calabasas, CA)
Assignee: KYTHERA BIOPHARMACEUTICALS, INC.
A61K31/575A61K38/08A61K45/06C07J9/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,522,155
App. No.
14/503,273
Granted
Dec 20, 2016
Kind
B2
Abstract

Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.

Claims (15)

1. A composition comprising about 0.1% w/v to about 2% w/v deoxycholic acid (DCA):

or a pharmaceutically acceptable salt thereof, wherein the DCA comprises a synthetic side chain of formula:

and at least one pharmaceutically acceptable excipient and/or carrier.

2. A method for removal of fat deposits in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a composition comprising DCA

or a pharmaceutically acceptable salt thereof, wherein the DCA comprises a synthetic side chain of formula:

and at least one pharmaceutically acceptable excipient and/or carrier.

3. The method of claim 2 , wherein the composition comprises about 0.1% w/v to about 2% w/v DCA or a pharmaceutically acceptable salt thereof.

4. The method of claim 2 , wherein the composition further comprises up to 5% w/v phosphatidylcholine.

5. The method of claim 2 , wherein the composition does not contain phosphatidylcholine.

6. A syringe or syringe-loadable container comprising a composition comprising DCA:

or a pharmaceutically acceptable salt thereof, wherein the DCA comprises a synthetic side chain of formula:

and at least one pharmaceutically acceptable excipient and/or carrier.

7. The syringe or syringe-loadable container of claim 6 , wherein the composition comprises about 0.1% w/v to about 2% w/v DCA or a pharmaceutically acceptable salt thereof.

8. The syringe or syringe-loadable container of claim 6 , wherein the composition further comprises up to 5% w/v phosphatidylcholine.

9. The syringe or syringe-loadable container of claim 6 , wherein the composition does not contain phosphatidylcholine.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Oct 17, 2019
From: KYTHERA BIOPHARMACEUTICALS, LLC; ALLERGAN SALES, LLC
To: ALLERGAN SALES, LLC
Reel/Frame 050754/0699 →
CHANGE OF NAME Recorded Oct 8, 2019
From: KYTHERA BIOPHARMACEUTICALS, INC.
To: KYTHERA BIOPHARMACEUTICALS, LLC
Reel/Frame 050672/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2016
From: MORIARTY, ROBERT M.; DAVID, NATHANIEL E.; MAHMOOD, NADIR AHMEDUDDIN
To: KYTHERA BIOPHARMACEUTICALS, INC.
Reel/Frame 039680/0185 →
Continuity (5)
Continuation 13741212 · Jan 14, 2013
Continuation 12035339 · Feb 21, 2008
Provisional Application 60956875 · Aug 20, 2007
Provisional Application 60945035 · Jun 19, 2007
Related Publication 20150094261A1 · Apr 2, 2015